Navigation Links
Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO)
Date:12/6/2010

About Cinryze® (C1 esterase inhibitor [human])

Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 esterase inhibitor product that has been approved by U.S. FDA for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE.  C1 inhibitor therapy has been used acutely for more than 35 years in Europe to treat patients with C1 inhibitor deficiency.

Severe hypersensitivity reactions to Cinryze may occur.  Thrombotic events have occurred in patients receiving Cinryze for routine prophylaxis, and in patients receiving off-label high dose C1 inhibitor therapy.  Monitor patients with known risk factors for thrombotic events.  With any blood or plasma derived product, there may be a risk of transmission of infectious agents, e.g. viruses and, theoretically, the CJD agent. The risk has been reduced by screening donors for prior exposure to certain virus infections and by manufacturing steps to reduce the risk of viral transmission including pasteurization and nanofiltration.  The most common adverse reactions observed have been upper respiratory infection, sinusitis, rash and headache. No drug-related serious adverse events (SAEs) have been observed in clinical trials.

Cinryze is for intravenous use only. A dose of 1000 Units of Cinryze can be administered every 3 or 4 days for routine prophylaxis against angioedema attacks in HAE patients. Cinryze is administered at an injection rate of 1 mL per minute.

About Hereditary Angioedema (HAE)

HAE is a rare, severely debilitating, life-threatening genetic disorder caused by a deficiency of C1 inhibitor, a human plasma protein. This condition is the result of a defect in the gene controlling the synthesis of C1 inhibitor. C1 inhibitor maintains the natural regulation of the contact, complement, and fibrinolytic systems, that when left unregulated, can initiate or perpetuate an attack by consu
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
2. ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
3. ViroPharma Files Prior Approval Supplement (PAS) for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Manufacturing
4. Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care
5. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
6. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
7. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
8. Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
9. Portola Pharmaceuticals Announces Data Presentations Highlighting Syk/JAK Inhibitor Clinical Development Program at 52nd American Society of Hematology Annual Meeting
10. VIDEO from Merck and Co., Inc available on thenewsmarket.com: In Phase III Study Mercks Investigational CETP Inhibitor Anacetrapib Met Safety and Efficacy Endpoints in Patients with CHD
11. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... NEW ORLEANS , May 22, 2013 /PRNewswire/ ... period for commercially-insured patients with Type 2 diabetes, ... shown to improve health outcomes and can lead ... studies presented at the International Society for Pharmacoeconomics ... The two studies, sponsored by Valeritas, ...
(Date:5/22/2013)... 2013   Life Line Screening  (LLS), a ... the creation of a unique partnership with MCM ... MCM is a population health management organization. LLS will ... clients. These important expanded services will help MCM and ... prevention reduces cost of care when individuals are able ...
(Date:5/22/2013)... May 22, 2013  Avanir Pharmaceuticals, Inc. (NASDAQ: ... overview of the company at the following conferences. ... Presentation date: Wednesday May 29, 2013 , Presentation time: ... Healthcare Conference , Presentation date: Wednesday June 5, 2013 ... A live webcast and 30-day archive of ...
Breaking Medicine Technology:Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 2Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 3Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 4Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 5Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 6Life Line Screening and MCM Solutions for Better Health Announce New Partnership 2Avanir Pharmaceuticals to Participate in Two Upcoming Investor Conferences 2
... MOUNTAIN VIEW, Calif. , Jan. 28 Omnicell, Inc. (Nasdaq: ... facilities, today announced results for its fourth quarter and year ended ... fourth quarter of 2009 was $54.7 million , up $0.7 ... $7.4 million or 11.9% from the fourth quarter of 2008. ...
... , SAN DIEGO , Jan. 28 ... Phase II clinical trial evaluating CTS-1027 in combination with pegylated ... activity, safety and tolerability of the triple combination will be ... is a significant unmet medical need in HCV patients who ...
Cached Medicine Technology:Omnicell Announces Fourth Quarter and Full-Year 2009 Results 2Omnicell Announces Fourth Quarter and Full-Year 2009 Results 3Omnicell Announces Fourth Quarter and Full-Year 2009 Results 4Omnicell Announces Fourth Quarter and Full-Year 2009 Results 5Omnicell Announces Fourth Quarter and Full-Year 2009 Results 6Omnicell Announces Fourth Quarter and Full-Year 2009 Results 7Omnicell Announces Fourth Quarter and Full-Year 2009 Results 8Omnicell Announces Fourth Quarter and Full-Year 2009 Results 9Omnicell Announces Fourth Quarter and Full-Year 2009 Results 10Omnicell Announces Fourth Quarter and Full-Year 2009 Results 11Omnicell Announces Fourth Quarter and Full-Year 2009 Results 12Omnicell Announces Fourth Quarter and Full-Year 2009 Results 13Omnicell Announces Fourth Quarter and Full-Year 2009 Results 14Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV) 2Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV) 3
(Date:5/22/2013)... 22, 2013 Recent tragedies including ... the school shooting in Newtown, Connecticut all resulted ... , Emergency medical practitioners train to respond ... Emergency Medical Services for Children (EMSC) Program specifically ... for the youngest patients. It is estimated 30 ...
(Date:5/22/2013)... May 22, 2013 Registered Dietitian and Founder ... today on Tatalou.com sharing a recipe for making energy bars ... Healthy Energy Bars ,” takes a recipe modified from one ... twists. , “Every day it gets more and more difficult ... said Chevreau. “The size of the nutrition label continues to ...
(Date:5/22/2013)... Finding trustworthy, loving child care is one of the most ... help parents in their search, Paty’s Daycare has launched ... programs, staff and much more. , “Our new website is ... said Patricia “Auntie Paty” Sutton, founder of Paty’s Daycare. “Just ... website, from the first time that you walk through the ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Pamela Isom, ... the Silicon Valley Business Journal’s 2013 Women of Influence ... and dedication. , The reception took place on ... for Women of Influence is particularly humbling for the ... year. The greatest success is to recognize the four ...
(Date:5/22/2013)... May 22, 2013 Go Classy the ... announced the launch of their newest website http://www.Desire-Mexico.com ... of like minds, Desire Resorts have become the premier ... a feeling of total liberation while allowing you to ... COO of Go Classy Tours / Caribbean-Hideaways. He goes ...
Breaking Medicine News(10 mins):Health News:When Tragedies Impact Children – Kentucky Emergency Medical Services for Children (KYEMSC) Offers Specialized Training for Pediatric Emergency Care 2Health News:How To "Make Your Own Healthy Energy Bars" 2Health News:Paty’s Daycare Launches New Website to Connect with Parents in Need of Nurturing Child Care 2Health News:Pamela Isom, President and CEO of ICE Safety Solutions Inc. Receives 2013 Women of Influence Recognition and Award 2Health News:Go Classy Tours Announces the Launch of Their Newest Website for Desire Resorts Located in Mexico Clothing Optional/Aunaturel Resorts a Lovers Paradise 2
... function without causing DNA damage , , FRIDAY, March 7 ... interaction involved in many types of cancer has been ... cultures, the small-molecule inhibitor MI-219 was highly effective at ... being blocked in the presence of a protein called ...
... of Telehealth capabilities to the ... they help across Canada., TORONTO, March 7 /PRNewswire/ - ... announce they have partnered with We,Care Health Services Inc. "We ... of services for those with chronic diseases,and their caregivers. We ...
... 7, Cancer,s two most,compelling words these ... holds capacity,to create patient heartache and promise, ... Cancer Network,s 13th Annual,Conference, March 5-9., ... dictate that,they follow guidelines created by NCCN ...
... Publishing and Penn,Hill Publications, based in Waltham, MA, ... News Media Contacts Directory. In addition to,publishing the ... Grey House is also proud to announce a ... In 1968, Howard Penn Hudson completed years of ...
... 7 Galderma Pharma, S.A.,announces an agreement with ... markets outside the USA and Canada for promotion ... partnership follows,an agreement signed last year between Galderma ... Pliaglis(TM) in the USA and Canada., "This ...
... 7 The rheumatoid arthritis (RA),treatment market, held back ... of Vioxx and Bextra, is rebounding due to the,performance ... RA topped $12 billion in 2006 and -- driven ... 11% a year through 2011,according to a new report ...
Cached Medicine News:Health News:Researchers Design Promising Cancer Drug 2Health News:We Care Health Services Inc. partners with IgeaCare Systems Inc. to deliver Healthanywhere(TM) for Chronic Disease Management in Canada. 2Health News:We Care Health Services Inc. partners with IgeaCare Systems Inc. to deliver Healthanywhere(TM) for Chronic Disease Management in Canada. 3Health News:Is Cancer Community in Alignment About 'Cure' and 'Costs'? NCCN Conference Panel Asks 2Health News:Is Cancer Community in Alignment About 'Cure' and 'Costs'? NCCN Conference Panel Asks 3Health News:Grey House Publishing Acquires Hudson's Washington News Media Contacts Directory 2Health News:Galderma Pharma, S.A. and ZARS Pharma, Inc. Extend Agreement to Cover Worldwide Rights for Pliaglis(TM) 2Health News:Galderma Pharma, S.A. and ZARS Pharma, Inc. Extend Agreement to Cover Worldwide Rights for Pliaglis(TM) 3Health News:In Post-Vioxx Era, Biologics are Reviving the Arthritis Treatment Market 2
... a range of Milli-Q ultrapure water ... quality requirements. Each of the five ... specifically target contaminants detrimental to particular ... and ICP-MS. The systems incorporate a ...
... developed a range of Milli-Q ultrapure ... water quality requirements. Each of the ... to specifically target contaminants detrimental to ... biology and ICP-MS. The systems incorporate ...
... a range of Milli-Q ultrapure water ... quality requirements. Each of the five ... specifically target contaminants detrimental to particular ... and ICP-MS. The systems incorporate a ...
... has developed a range of Milli-Q ... specific water quality requirements. Each of ... designed to specifically target contaminants detrimental ... molecular biology and ICP-MS. The systems ...
Medicine Products: